Floatz logo

Clenbuterol

Pompe Disease (Late-onset)

Duke UniversitySmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
89/ 100

Competitive context

11 Active assets in the Pompe Disease (Late-onset) cohort.

Asset / SponsorPhaseRating
Alglucosidase Alfa
Erasmus Medical Center
Phase 4BBB
Cipaglucosidase Alfa-ATGA
Amicus Therapeutics
Phase 3BB
Avalglucosidase Alfa
Iris Plug
Phase 4BB
Miglustat
Amicus Therapeutics
Phase 3B
at2221
Amicus Therapeutics
Phase 3B

View all 13 →

Same molecule, other indications

Clenbuterol is also rated in:

Mild Cognitive Impairment, Lewy Body Dementia, Parkinson's Disease Rapid Eye Movement Sleep Behavior Disorder, Parkinson's Disease DementiaDormant
B
Indicative ·
57 / 100
View asset →
amyotrophic lateral sclerosisDormant
CCC
Indicative ·
54 / 100
View asset →
type 2 diabetes mellitusDormant
CCC
Indicative ·
54 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →